Patents by Inventor Mary Richardson

Mary Richardson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10709631
    Abstract: A compression garment for a neurological disorder includes a body portion and a pad. The body portion may be operable to wrap around a foot and the pad can attach to an inner surface of the body portion. The pad can include an outward protrusion and/or an inward recess. A guide sleeve may be dimensioned to wrap together with the body portion around the foot, the pad being disposable between the body portion and the guide sleeve. A first tensioning band may be attached onto to first and second locations of the body portion and be operable to secure opposing first and second portions of the inner surface of the body portion to secure the outward protrusion and/or recess of the pad against the abductor hallucis and flexor hallucis brevis muscles of the foot. The outward protrusion can include a receiver for the metatarsal head.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 14, 2020
    Assignee: MEDI USA, L.P.
    Inventors: Kevin Larmer, Moses Lipshaw, Thomas Richardson, Karen Lynch, Glenn Anderson, Dean Bender, Chris Majors, Mary Sorg
  • Publication number: 20190047978
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: October 16, 2018
    Publication date: February 14, 2019
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Patent number: 10112923
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 30, 2018
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20170291888
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A21, or, particularly, the A2, receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: November 4, 2016
    Publication date: October 12, 2017
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20160175314
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: December 21, 2015
    Publication date: June 23, 2016
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Patent number: 9249130
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: February 2, 2016
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20150005276
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: July 2, 2014
    Publication date: January 1, 2015
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Patent number: 8809525
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: August 19, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20130029963
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: February 7, 2011
    Publication date: January 31, 2013
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20080228095
    Abstract: A multi-functional, hand-held medical device for measuring bodily functions and physiological parameters and for medical screening and diagnosis by dual sound detection. A multi-functional, hand-held medical device capable of accurate, automatic and instantaneous readings of data received from the patient's different bodily functions, enhances productivity of the user, allows for flexibility to adjust the distance between the patient and the user, and reduces the potential for transmission of infectious or contagious organisms between the patient and the user. A multi-functional, hand-held medical device that does not require the use of earpieces. A method for measuring bodily functions and physiological parameters and for medical screening and diagnosis by dual sound detection.
    Type: Application
    Filed: March 15, 2007
    Publication date: September 18, 2008
    Inventor: Mary RICHARDSON
  • Publication number: 20080010785
    Abstract: A system for splicing a conveyor belt with belt fasteners is disclosed. A base assembly aligns the belt, belt fasteners and rivet holes thereof with swage structures for securing the rivets. A guide assembly has a rigid guide block with cylindrical pilot holes, and a guide membrane of resilient material. Guide pins are receivable by guide bores for aligning the base and guide assemblies with the pilot holes, rivet holes, and swage structures in registry. The guide membrane including openings aligned with the pilot holes. The openings have a pair of slits defining flaps deflectable to permit the rivet to pass therethrough, and a central hole or cut-out. The flaps and the cut-out assist in centering the rivet with the belt fastener rivet holes. The system uses a single-rivet driver, a multi-rivet driver, a pneumatic driver, or an electric hammer.
    Type: Application
    Filed: April 4, 2006
    Publication date: January 17, 2008
    Inventors: Thomas Richardson, Mary Richardson
  • Publication number: 20050286254
    Abstract: A base for a lantern. The base provides a stable platform for supporting the lantern and prevents tipping of the lantern. The base may be used with fuel burning lanterns or lanterns that utilize batteries or other power sources. The base includes foldable feet. The feet fold out of a plane of the base for storage, for example, downward from the plane. The base is turned over and the feet, when folded (upward when the base is upside down), extend upward around a portion of the lantern during storage. This configuration provides convenient, compact storage of the lantern and base, so that the base may be stored with the lantern and may protect the lantern in storage.
    Type: Application
    Filed: June 20, 2005
    Publication date: December 29, 2005
    Applicant: The Coleman Company, Inc.
    Inventors: Mary Richardson, Todd Showalter, Duane Marshall, Vernon Taylor, Timothy Holub
  • Patent number: 6197495
    Abstract: A novel Staphylococcus glycyl tRNA synthetase crystalline structure is identified. Also disclosed are methods of identifying inhibitors of these synthetases and/or active sites, and inhibitors identified by these methods.
    Type: Grant
    Filed: May 10, 1998
    Date of Patent: March 6, 2001
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham plc
    Inventors: Xiayang Qiu, Neal Frederick Osborne, Christine Mary Richardson, Cheryl A. Janson
  • Patent number: 6037117
    Abstract: A novel Staphylococcus glycyl tRNA synthetase crystalline structure is identified. Also disclosed are methods of identifying inhibitors of these synthetases and/or active sites, and inhibitors identified by these methods.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: March 14, 2000
    Assignees: Smithkline Beecham Corporation, Smithkline Beecham plc
    Inventors: Xiayang Qiu, Neal Frederick Osborne, Christine Mary Richardson, Cheryl A. Janson
  • Patent number: D734178
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: July 14, 2015
    Assignee: ecobee, Inc.
    Inventors: Stuart Lombard, Mark Malchiondo, Nash Qadri, Hesham Fahmy, Mary Richardson, Christina Tiffin, Marcelle Van Beusekom, Jonathan Mendoza, Jeff Salazar, Wenson Chern
  • Patent number: D737153
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: August 25, 2015
    Assignee: ecobee, Inc.
    Inventors: Stuart Lombard, Mark Malchiondo, Nashib Qadri, Hesham Fahmy, Mary Richardson, Christina Tiffin, Marcelle Van Beusekom, Jonathan Mendoza, Jeffrey Allen Salazar, Wenson Chern